Show
Sort by
-
Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia
-
- Journal Article
- A1
- open access
Aboveground biomass density models for NASA’s Global Ecosystem Dynamics Investigation (GEDI) lidar mission
-
- Journal Article
- A1
- open access
Novel antibody cocktail targeting Bet v 1 rapidly and sustainably treats birch allergy symptoms in a Phase 1 study
-
- Journal Article
- A1
- open access
Tree diversity effects on soil microbial biomass and respiration are context dependent across forest diversity experiments
-
Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials
-
Anti-Bet v_1 MABs reduced basophil responsiveness to birch pollen stimulation ex-vivo in birch allergic patients
(2020) ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY. In Annals of Allergy Asthma & Immunology 125(5). p.S19-S19 -
Anti-Bet v_1 MAB cocktail reduced birch allergic symptoms within one week, sustained over two months
(2020) ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY. In Annals of Allergy Asthma & Immunology 125(5). p.S19-S19 -
Evaluating the potential of full‐waveform lidar for mapping pan‐tropical tree species richness
-
- Miscellaneous
- open access
Biotic and abiotic drivers of soil microbial functions across tree diversity experiments
-
Definition of synchronous oligometastatic non–small cell lung cancer : a consensus report
-
- Journal Article
- A1
- open access
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT) : an open-label, phase 3, randomised, superiority trial
-
Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: a single-arm phase II study (EORTC-08061)
-
Maintenance pazopanib versus placebo in non-small cell lung cancer patients non-progressive after first line chemotherapy: a double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064)
-
Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation
-
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052)
-
Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma
-
Treatment for non small cell lung cancer, small cell lung cancer and pleural mesothelioma within the EORTC Lung Cancer Group: past, present and future
-
Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer: EORTC 08062
-
Response to chemotherapy predicts longer survival in an individual patient meta-analysis of 1205 patients with mesothelioma
-
An alternative biological scaffold for tissue valve engineering: in vivo evaluation of kangaroo and porcine aortic valve matrices in sheep